Ipamorelin vs GHRP-6: What the Research Compares

Ipamorelin and GHRP-6 are two synthetic peptides that are usually grouped together in the same pharmacological family, the growth hormone secretagogues. Because they are discussed together so often, the obvious question is whether anyone has actually tested them against each other. This page sets out what the indexed literature contains, in what order of evidence strength, and what it does not contain. It does not rank the two peptides, does not name a preferred compound, and does not describe any protocol. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or any compound discussed here.

Head to Head Trials: What Exists and What Does Not

Stated plainly: in the literature reviewed for this page there is no randomized controlled trial in humans that assigned participants to an ipamorelin arm and a GHRP-6 arm and measured a primary clinical endpoint such as body composition, bone density, appetite or recovery. No named human trial of that design exists to summarise. Narrative reviews of growth hormone and IGF-1 axis peptides describe the clinical evidence base for secretagogues as limited and note the gap between that evidence and widespread self-administration (PMID 42395176).

Two published studies did expose the same experimental subjects or the same experimental design to both peptides. Both are described below, and neither was a clinical efficacy trial.

Direct preclinical comparison: bone mineral content in adult female rats

The closest thing to a comparative experiment is a 2000 study in The Journal of Endocrinology, in which researchers administered the growth hormone secretagogues ipamorelin and GH-releasing peptide-6 to adult female rats and reported that both compounds increased bone mineral content (PMID 10828840). The study population was rats rather than humans, the endpoint was a densitometric measure rather than fractures or clinical outcomes, and the design did not establish any comparative clinical claim between the two peptides (PMID 10828840).

Direct human comparison of a non clinical endpoint: urinary metabolites

A 2015 Drug Testing and Analysis study administered GHRP-1, GHRP-2, GHRP-6, hexarelin and ipamorelin by the nasal route and determined the resulting growth hormone releasing peptide metabolites in human urine (PMID 25869809). That study put both peptides in the same protocol, but the endpoint researchers measured was analytical detectability for anti doping purposes, not efficacy, body composition or safety (PMID 25869809).

Side by Side: The Two Separate Evidence Bases

Class and Mechanism as Described in the Literature

Both peptides are discussed as agents that act on the ghrelin receptor system rather than on the growth hormone receptor itself. A 2001 paper in Endocrine examined whether growth hormone releasing peptides act as ghrelin secretagogues, framing the relationship between synthetic GHRPs and the endogenous ghrelin system (PMID 11322495). Ipamorelin has been characterised in pharmacology work as a ghrelin mimetic, including in the rodent postoperative ileus study (PMID 19289567).

One mechanistic point that appears across the secretagogue literature is that not every observed effect is downstream of growth hormone. A 2001 report in Biochemical and Biophysical Research Communications described growth hormone independent stimulation of adiposity by growth hormone secretagogues, indicating that some metabolic effects of this class did not require intact growth hormone signalling (PMID 11162489). Chronic exposure effects on the pituitary itself have also been studied for one of the two compounds: a 2002 histology and histopathology paper reported on the somatotroph response in vitro after chronic treatment with ipamorelin in young female rats (PMID 12168778).

What the Ipamorelin Literature Covers

The ipamorelin record in this citation set is mostly preclinical. Researchers evaluated the peptide in a rodent model of postoperative ileus and published the results as an efficacy study in The Journal of Pharmacology and Experimental Therapeutics (PMID 19289567). Skeletal effects were addressed in the rat bone mineral content study that also included GHRP-6 (PMID 10828840). Pituitary adaptation after repeated exposure was addressed in the young female rat somatotroph study (PMID 12168778).

On the human side, ipamorelin appears mainly in review and analytical literature rather than in controlled trials. A 2020 review in Translational Andrology and Urology discussed growth hormone secretagogues in the context of body composition management in hypogonadal males (PMID 32257855), and a 2026 narrative review in Sexual Medicine Reviews covered peptides used in urology and sexual medicine including questions of effectiveness, indications and safety (PMID 42862021).

What the GHRP-6 Literature Covers

GHRP-6 is the older of the two compounds and sits inside the broader growth hormone releasing peptide family that includes GHRP-1, GHRP-2 and hexarelin, all of which were studied together in the human nasal administration excretion work (PMID 25869809). Its relationship to endogenous ghrelin signalling was the subject of the 2001 Endocrine analysis of whether GHRPs act as ghrelin secretagogues (PMID 11322495). Its skeletal effect in rodents was reported in the same study that tested ipamorelin (PMID 10828840). Reviews of the GH-IGF1 axis peptide landscape place GHRP-6 among the compounds used outside clinical supervision and describe the resulting gap between published evidence and real world use (PMID 42395176).

Regulatory Status and Product Quality Findings

Neither ipamorelin nor GHRP-6 has an approved drug product for general therapeutic use in the United States, and both circulate largely as research chemicals and as unapproved material. Reviews of performance oriented peptide use describe self-administration occurring outside of approved indications and outside clinical oversight (PMID 42395176). Analytical chemistry work has repeatedly examined what unregulated products actually contain: a 2018 study in Growth Hormone and IGF Research analysed new growth promoting black market products (PMID 29864719), and a 2019 Drug Testing and Analysis paper identified glycine-modified growth hormone secretagogues in seized doping material (PMID 30136411). Those findings concern product identity and composition rather than the pharmacology of either peptide.

Anti doping laboratories treat both compounds as screening targets. A 2016 method paper in the Journal of Separation Science described simplified screening for peptides under 2 kDa using direct urine injection, liquid chromatography and ion mobility mass spectrometry (PMID 26578461), and the nasal administration study mapped the specific urinary metabolites that make GHRP-6 and ipamorelin detectable (PMID 25869809). Regulatory and sport eligibility rules vary by country and by organisation, and nothing here is legal advice.

Adverse Events: What Studies Report

The verified citation set does not contain a large randomized human safety trial of either peptide, and it contains no safety comparison between them. What is reported falls into three groups.

• Class level metabolic observations. Researchers reported growth hormone independent stimulation of adiposity by growth hormone secretagogues, meaning that fat accrual effects in that model did not depend on growth hormone signalling (PMID 11162489).
• Pituitary adaptation in animals. Chronic treatment with ipamorelin in young female rats was studied specifically for the somatotroph response measured in vitro (PMID 12168778).
• Risks tied to unregulated supply. Reviews describe patient self-administration of GH-IGF1 axis peptides as occurring without the safety data that would normally accompany clinical use (PMID 42395176), and analytical studies of black market and seized material documented what those products contained (PMID 29864719, PMID 30136411). Narrative reviews covering peptide use in urology and sexual medicine also addressed safety as an open question rather than a settled one (PMID 42862021).

Limits of Any Ipamorelin Versus GHRP-6 Comparison

Several limits apply to every statement on this page. First, the single study that tested both peptides under the same protocol with a biological endpoint used rats, and its endpoint was bone mineral content (PMID 10828840). Second, the single human study containing both peptides measured urinary metabolites rather than any health outcome (PMID 25869809). Third, review level sources describe the clinical evidence for this peptide class as thin relative to how widely the compounds are discussed (PMID 42395176, PMID 32257855). Comparative statements that go beyond those boundaries are not supported by the published record summarised here.

Related reading: GHRP-6 research overview.

References

• The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats (The Journal of Endocrinology, 2000)
• Growth hormone (GH)-independent stimulation of adiposity by GH secretagogues (Biochemical and Biophysical Research Communications, 2001)
• Do growth hormone-releasing peptides act as ghrelin secretagogues? (Endocrine, 2001)
• Influence of chronic treatment with the growth hormone secretagogue Ipamorelin, in young female rats: somatotroph response in vitro (Histology and Histopathology, 2002)
• Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus (The Journal of Pharmacology and Experimental Therapeutics, 2009)
• Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin (Drug Testing and Analysis, 2015)
• Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry (Journal of Separation Science, 2016)
• Analysis of new growth promoting black market products (Growth Hormone & IGF Research, 2018)
• Glycine-modified growth hormone secretagogues identified in seized doping material (Drug Testing and Analysis, 2019)
• Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males (Translational Andrology and Urology, 2020)
• The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration (Frontiers in Endocrinology, 2026)
• Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review (Sexual Medicine Reviews, 2026)